skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration
By 2035, the incidence and mortality in these cancers is expected to rise by rates of 51-97% and 63-101%, respectively.  Therefore it is imperative that the current clinical landscape of these cancers be examined and thoroughly understood in order to aid in the strategic planning needed to facilitate development of effective therapies to combat these cancers in the future. Using data exported from Citeline’s competitive intelligence product suite in April 2014, an analysis of over 6500 trials from 1988 to 2014 in these five prevalent Asian cancers included locations, sponsorship, recent clinical activity, primary drugs and mechanisms of action, primary endpoints and incorporation of pharmacogenomic biomarkers. Supportive care trials in these five cancers were excluded from this analysis.

Highlights in this white paper include:

This important white paper provides an in-depth analysis of the clinical trial landscape in 10 Asian countries related to effective therapies of treatment of the five most prevalent and life-threatening Asian cancers.

 

Top Five Asian Cancers – Trends in Clinical Development

  • Cancer types by clinical trial locations for all trial statuses
  • Trial activity by sponsor types, including industry and non-industry groups
  • Recent clinical activity and sponsor investment by cancer type and the reasons behind trends in sponsorship
  • Primary drugs and mechanisms of action
  • The distribution of primary endpoints and more
asian cancers
Download white paper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now